Investment Analysts’ Weekly Ratings Changes for Marinus Pharmaceuticals (MRNS)

Several brokerages have updated their recommendations and price targets on shares of Marinus Pharmaceuticals (NASDAQ: MRNS) in the last few weeks:

• 11/18/2024 – Marinus Pharmaceuticals is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 11/14/2024 – Marinus Pharmaceuticals had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $4.00 price target on the stock.
• 11/14/2024 – Marinus Pharmaceuticals had its “neutral” rating reaffirmed by analysts at HC Wainwright. They now have a $2.00 price target on the stock.
• 11/10/2024 – Marinus Pharmaceuticals is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 11/2/2024 – Marinus Pharmaceuticals is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 10/25/2024 – Marinus Pharmaceuticals had its price target lowered by analysts at Royal Bank of Canada from $3.00 to $1.00. They now have a “sector perform” rating on the stock.
• 10/25/2024 – Marinus Pharmaceuticals had its price target lowered by analysts at Cantor Fitzgerald from $13.00 to $4.00. They now have an “overweight” rating on the stock.
• 10/25/2024 – Marinus Pharmaceuticals had its “neutral” rating reaffirmed by analysts at HC Wainwright.
• 10/25/2024 – Marinus Pharmaceuticals had its “hold” rating reaffirmed by analysts at TD Cowen.
• 10/25/2024 – Marinus Pharmaceuticals had its “hold” rating reaffirmed by analysts at Jefferies Financial Group Inc.. They now have a $0.50 price target on the stock, down previously from $5.00.
• 10/24/2024 – Marinus Pharmaceuticals had its “market perform” rating reaffirmed by analysts at JMP Securities.
• 10/24/2024 – Marinus Pharmaceuticals was downgraded by analysts at Truist Financial Co. from a “strong-buy” rating to a “hold” rating.
• 10/4/2024 – Marinus Pharmaceuticals was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating.
• 9/30/2024 – Marinus Pharmaceuticals was upgraded by analysts at EF Hutton Acquisition Co. I to a “strong-buy” rating.
• 9/26/2024 – Marinus Pharmaceuticals was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating.
• 9/24/2024 – Marinus Pharmaceuticals had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $13.00 price target on the stock.
• 9/23/2024 – Marinus Pharmaceuticals was upgraded by analysts at Oppenheimer Holdings Inc. from a “market perform” rating to an “outperform” rating. They now have a $6.00 price target on the stock.
• 9/23/2024 – Marinus Pharmaceuticals had its “market outperform” rating reaffirmed by analysts at JMP Securities. They now have a $10.00 price target on the stock.

Marinus Pharmaceuticals Stock Performance

Shares of MRNS opened at $0.31 on Friday. The stock has a fifty day moving average of $1.15 and a two-hundred day moving average of $1.29. Marinus Pharmaceuticals, Inc. has a fifty-two week low of $0.26 and a fifty-two week high of $11.26. The company has a market capitalization of $17.10 million, a PE ratio of -0.13 and a beta of 1.26.

Institutional Trading of Marinus Pharmaceuticals

A number of large investors have recently modified their holdings of the company. Renaissance Technologies LLC purchased a new stake in Marinus Pharmaceuticals in the 2nd quarter worth about $727,000. Vanguard Group Inc. boosted its stake in Marinus Pharmaceuticals by 5.0% during the 1st quarter. Vanguard Group Inc. now owns 2,805,920 shares of the biopharmaceutical company’s stock valued at $25,366,000 after purchasing an additional 132,689 shares during the period. Acadian Asset Management LLC bought a new position in Marinus Pharmaceuticals during the second quarter worth $813,000. Hussman Strategic Advisors Inc. grew its position in Marinus Pharmaceuticals by 14.3% during the second quarter. Hussman Strategic Advisors Inc. now owns 84,000 shares of the biopharmaceutical company’s stock worth $98,000 after buying an additional 10,500 shares in the last quarter. Finally, Squarepoint Ops LLC bought a new position in shares of Marinus Pharmaceuticals during the 2nd quarter worth about $206,000. Institutional investors and hedge funds own 98.80% of the company’s stock.

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.